MX9704201A - Compuestos de xantina que tienen cadenas laterales de alquinol aminadas terminalmente. - Google Patents

Compuestos de xantina que tienen cadenas laterales de alquinol aminadas terminalmente.

Info

Publication number
MX9704201A
MX9704201A MX9704201A MX9704201A MX9704201A MX 9704201 A MX9704201 A MX 9704201A MX 9704201 A MX9704201 A MX 9704201A MX 9704201 A MX9704201 A MX 9704201A MX 9704201 A MX9704201 A MX 9704201A
Authority
MX
Mexico
Prior art keywords
compounds
xantine
side chains
alkynol
terminally aminated
Prior art date
Application number
MX9704201A
Other languages
English (en)
Other versions
MXPA97004201A (es
Inventor
Ulrich Gebert
Elisabeth Defossa
Uwe Heinelt
Karl Rudolphi
John J Grome
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19622734A external-priority patent/DE19622734A1/de
Priority claimed from DE1996136882 external-priority patent/DE19636882A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MXPA97004201A publication Critical patent/MXPA97004201A/es
Publication of MX9704201A publication Critical patent/MX9704201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la formula I: en la que por lo menos uno de los radicales R1 y R3 representan un radical de alquinol de la formula Ia o Ib se adecuan para la preparacion de medicamentos con un efecto neuroprotector.
MX9704201A 1996-06-07 1997-06-06 Compuestos de xantina que tienen cadenas laterales de alquinol aminadas terminalmente. MX9704201A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19622734A DE19622734A1 (de) 1996-06-07 1996-06-07 Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten
DE19622734.8 1996-06-07
DE19636882.0 1996-09-11
DE1996136882 DE19636882A1 (de) 1996-09-11 1996-09-11 Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten

Publications (2)

Publication Number Publication Date
MXPA97004201A MXPA97004201A (es) 1998-04-01
MX9704201A true MX9704201A (es) 1998-04-30

Family

ID=26026371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704201A MX9704201A (es) 1996-06-07 1997-06-06 Compuestos de xantina que tienen cadenas laterales de alquinol aminadas terminalmente.

Country Status (26)

Country Link
US (1) US5965555A (es)
EP (1) EP0811623B1 (es)
JP (1) JP4263778B2 (es)
KR (1) KR100531964B1 (es)
CN (1) CN1064361C (es)
AR (1) AR013821A1 (es)
AT (1) ATE200288T1 (es)
AU (1) AU712717B2 (es)
BR (1) BR9703500B1 (es)
CA (1) CA2207258C (es)
CZ (1) CZ292509B6 (es)
DE (1) DE59703271D1 (es)
DK (1) DK0811623T3 (es)
ES (1) ES2155640T3 (es)
GR (1) GR3035711T3 (es)
HU (1) HU224702B1 (es)
ID (1) ID17468A (es)
IL (1) IL120998A (es)
MX (1) MX9704201A (es)
MY (1) MY117764A (es)
NO (1) NO307787B1 (es)
NZ (1) NZ328018A (es)
PL (1) PL186238B1 (es)
PT (1) PT811623E (es)
RU (1) RU2204561C2 (es)
TW (1) TW384289B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2284708A (en) * 1993-12-07 1995-06-14 At & T Corp Method for passivation of multi-quantum well infrared photodetectors (QWIPS) to reduce dark current and to improve dark current uniformity
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
WO2003008559A2 (en) * 2001-07-19 2003-01-30 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2496249C (en) * 2002-08-21 2012-01-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
AR071175A1 (es) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007197A (en) * 1975-06-10 1977-02-08 The Dow Chemical Company Process for preparing phosphorothioates and phenylphosphonothioates
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono

Also Published As

Publication number Publication date
TW384289B (en) 2000-03-11
PL186238B1 (pl) 2003-12-31
AR013821A1 (es) 2001-01-31
IL120998A (en) 2000-07-16
US5965555A (en) 1999-10-12
EP0811623A1 (de) 1997-12-10
MY117764A (en) 2004-08-30
NZ328018A (en) 1998-09-24
RU2204561C2 (ru) 2003-05-20
HUP9701018A2 (hu) 1998-12-28
HUP9701018A3 (en) 2000-01-28
ES2155640T3 (es) 2001-05-16
BR9703500B1 (pt) 2010-05-18
KR100531964B1 (ko) 2006-03-17
HU9701018D0 (en) 1997-07-28
DE59703271D1 (de) 2001-05-10
CA2207258A1 (en) 1997-12-07
ID17468A (id) 1998-01-08
IL120998A0 (en) 1997-11-20
CN1169994A (zh) 1998-01-14
PT811623E (pt) 2001-09-28
CN1064361C (zh) 2001-04-11
JP4263778B2 (ja) 2009-05-13
HU224702B1 (en) 2006-01-30
BR9703500A (pt) 1998-10-06
EP0811623B1 (de) 2001-04-04
ATE200288T1 (de) 2001-04-15
JPH1059968A (ja) 1998-03-03
KR19980024046A (ko) 1998-07-06
NO307787B1 (no) 2000-05-29
NO972581L (no) 1997-12-08
GR3035711T3 (en) 2001-07-31
PL320414A1 (en) 1997-12-08
CZ174297A3 (en) 1997-12-17
NO972581D0 (no) 1997-06-06
CA2207258C (en) 2006-08-08
AU712717B2 (en) 1999-11-11
AU2469997A (en) 1997-12-11
DK0811623T3 (da) 2001-07-23
CZ292509B6 (cs) 2003-10-15

Similar Documents

Publication Publication Date Title
MX9704201A (es) Compuestos de xantina que tienen cadenas laterales de alquinol aminadas terminalmente.
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
ZA988826B (en) Acylsulfamoylbenzamides crop protection compositions comprising them and processes for their preparation
GB2301106B (en) Synergistic stabilizer mixture
HK1023064A1 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
IL112495A0 (en) Phenylacetic acid derivatives, their preparation and compositions containing them
BG103251A (en) Oxydiazols, methods for their preparation and application as medicamentous forms
AU4461193A (en) 9-{substituted glycyl)amido}-6-demethyl-6-deoxyte tracyclines
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
MY117798A (en) Use of a rapamycin derivative in vasculopathies and xenotransplantation
LV10924A (lv) Sintetiskie katalitiskie brivo radikalu akceptori kurus izmanto ka antioksidantus slimibu profilaksei un arstesanai
IL114294A0 (en) Sterol derivatives
GEP20074185B (en) Incclusion complexs of aryl- heterocyclic salts
IT1285770B1 (it) Composti corticoidei
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
HK1067365A1 (en) Tetrahydropyrido compounds
DE69113221D1 (en) Antiatherosclerotische und antithrombotische 2-amino-6-phenyl-4h-pyran-4-one.
MXPA01011606A (es) Terapia anti-inflamatoria para infeccion mediada por inflamacion.
AU4772399A (en) Use of 2,2,6,6 tetraalkylpiperidine-n-oxyl radicals having long alkyl chains as polymerization regulators
GR3006349T3 (es)
IL157050A0 (en) 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
ZA953700B (en) Novel sulfenamide accelerators and rubber compositions containing the same
MY107976A (en) Improvements in or relating to organic compounds

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees